Osteoporosis is a progressive skeletal disease which is characterized by reduced bone mass and degradation of bone microstructure. Mesenchymal stem cells (MSCs) have the potential to inhibit osteoporosis since they are multipotent stem cells that can differentiate into multiple types of cells including osteoblasts. Hence the mechanism of osteogenic differentiation of MSCs deserves comprehensive study. Here we report that KLF9 is a novel regulator in osteogenic differentiation of MSCs. We observed that depletion of KLF9 can largely compromise the osteogenic differentiation ability of MSCs. In addition, we revealed that inhibition of the PI3K-Akt pathway could also affect osteogenic differentiation since KLF9 depletion inhibits PI3K expression. Finally, we discovered that KLF9 expression can be induced by dexamethasone which is an essential component in osteogenic induction medium. Taken together, our study provides new insights into the regulatory role of KLF9 in osteogenic differentiation of MSCs.
Keyphrases
- mesenchymal stem cells
- umbilical cord
- transcription factor
- bone marrow
- bone mineral density
- stem cells
- cell therapy
- poor prognosis
- postmenopausal women
- low dose
- multiple sclerosis
- induced apoptosis
- body composition
- risk assessment
- white matter
- cell cycle arrest
- signaling pathway
- long non coding rna
- endoplasmic reticulum stress
- human health
- pi k akt